Bevacizumab/paclitaxelDysphonia: 4 case reports

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2014年 / 1518卷 / 1期

关键词：

D O I：

10.1007/s40278-014-3299-7

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：47 / 47

相关论文

共 50 条

[31] Bevacizumab/cetuximab/irinotecanDevelopment of chemotherapy resistance and disease progression: 4 case reports
Reactions Weekly, 2015, 1533 (1) : 87 - 87
[32] Bevacizumab/doxorubicinMyelosuppression and hypertension: 3 case reports
Reactions Weekly, 2022, 1888 (1) : 103 - 103
[33] Bevacizumab/fluorouracilOral mucositis: 3 case reports
Reactions Weekly, 2011, 1370 (1) : 11 - 11
[34] Bevacizumab/cetuximabPulmonary toxicities: 3 case reports
Reactions Weekly, 2021, 1868 (1) : 113 - 113
[35] Bevacizumab/carmustineVarious toxicities: 8 case reports
Reactions Weekly, 2018, 1690 (1) : 43 - 43
[36] Bevacizumab/ranibizumab/triamcinoloneEndophthalmitis: 21 case reports
Reactions Weekly, 2011, 1377 (1) : 11 - 11
[37] Bevacizumab/irinotecanHepatotoxicity and proteinurea: 2 case reports
Reactions Weekly, 2016, 1618 (1) : 42 - 42
[38] Bevacizumab/ranibizumabOcular hypertension: 10 case reports
Reactions Weekly, 2021, 1877 (1) : 71 - 71
[39] Bevacizumab/irinotecanNeutropenia and mucositis: 2 case reports
Reactions Weekly, 2021, 1871 (1) : 96 - 96
[40] Bevacizumab/doxorubicinCardiac toxicities: 6 case reports
Reactions Weekly, 2012, 1405 (1) : 11 - 11

← 1 2 3 4 5 →